ZA202202712B - Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells - Google Patents

Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Info

Publication number
ZA202202712B
ZA202202712B ZA2022/02712A ZA202202712A ZA202202712B ZA 202202712 B ZA202202712 B ZA 202202712B ZA 2022/02712 A ZA2022/02712 A ZA 2022/02712A ZA 202202712 A ZA202202712 A ZA 202202712A ZA 202202712 B ZA202202712 B ZA 202202712B
Authority
ZA
South Africa
Prior art keywords
antimitoscins
stem cells
cancer stem
mitochondrial biogenesis
targeted inhibitors
Prior art date
Application number
ZA2022/02712A
Inventor
P Lisanti Michael
Sotgia Federica
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of ZA202202712B publication Critical patent/ZA202202712B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Antibiotics in the erythromycin family having intrinsic anti-mitochondrial properties may be chemically modified to target the antibiotics to mitochondria, and the resulting "antimitoscins" may have enhanced anti-cancer properties, among other advantageous properties. Also described are methods of using a compound comprising a member of the erythromycin family modified with at least one membrane targeting signal to target cancer, and pharmaceutical compositions for treating cancer containing a member of the erythromycin family modified with at least one membrane targeting signal, as the active ingredient.
ZA2022/02712A 2017-05-19 2022-03-07 Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells ZA202202712B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508702P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
ZA202202712B true ZA202202712B (en) 2023-11-29

Family

ID=64274780

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA2019/07654A ZA201907654B (en) 2017-05-19 2019-11-19 Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
ZA2021/02509A ZA202102509B (en) 2017-05-19 2021-04-16 Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
ZA2022/02712A ZA202202712B (en) 2017-05-19 2022-03-07 Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ZA2019/07654A ZA201907654B (en) 2017-05-19 2019-11-19 Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
ZA2021/02509A ZA202102509B (en) 2017-05-19 2021-04-16 Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Country Status (20)

Country Link
US (2) US11160821B2 (en)
EP (1) EP3624840A4 (en)
JP (1) JP6938682B2 (en)
KR (1) KR20200010343A (en)
CN (1) CN111315400A (en)
AU (1) AU2018270129B2 (en)
BR (1) BR112019024264A2 (en)
CA (1) CA3063717C (en)
CL (1) CL2019003283A1 (en)
CO (1) CO2019012888A2 (en)
CR (1) CR20190524A (en)
CU (1) CU20190092A7 (en)
DO (1) DOP2019000294A (en)
EC (1) ECSP19082194A (en)
IL (1) IL270598B (en)
MX (1) MX2019013735A (en)
PE (1) PE20200605A1 (en)
RU (1) RU2019142102A (en)
WO (1) WO2018213751A1 (en)
ZA (3) ZA201907654B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195446A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
RU2019142102A (en) 2017-05-19 2021-06-21 Лунелла Байотек, Инк. ANTIMITOSCINS: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS FOR ERADICATION OF MALIGNANT STEM CELLS
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CN110913854B (en) 2017-06-26 2023-04-28 卢内拉生物技术有限公司 mitokotoscin: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
EP3695005B1 (en) 2017-10-11 2023-12-06 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
EP3717015A4 (en) * 2017-12-01 2021-07-28 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CA3114888A1 (en) 2018-10-02 2020-04-09 Lunella Biotech, Inc. Azithromycin and roxithromycin derivatives as senolytic drugs
BR112021011964A2 (en) 2018-12-17 2021-09-08 Lunella Biotech, Inc. TRIPLE COMBINATION THERAPIES FOR ANTI-AGING
AU2019403048A1 (en) * 2018-12-17 2021-07-08 Lunella Biotech, Inc. Triple combination therapies for targeting mitochondria and killing cancer stem cells
EP3976197A4 (en) * 2019-05-24 2023-07-19 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer
CA3144666A1 (en) * 2019-06-26 2020-12-30 Lunella Biotech, Inc. Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells
EP4048246A4 (en) * 2019-10-24 2023-01-25 The Medical College of Wisconsin, Inc. Mitochondria-targeted atovaquone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug
WO2021229499A1 (en) * 2020-05-13 2021-11-18 Lunella Biotech, Inc. Myristoyl derivatives of 9-amino-doxycycline for targeting cancer stem cells and preventing metastasis
CN116437922A (en) * 2020-10-22 2023-07-14 卢内拉生物技术有限公司 Gamma subunit targeted mitochondrial ATP inhibitors for preventing metastasis

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862921A (en) * 1953-08-13 1958-12-02 Upjohn Co Erythromycin esters
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DK149776C (en) * 1984-01-06 1987-04-21 Orion Yhtymae Oy ANTIBIOTIC EFFECT OF ERYTHROMYCIN COMPOUND AND PREPARATION CONTAINING THE COMPOUND
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
US6165999A (en) 1995-05-03 2000-12-26 Pfizer Inc Tetracycline derivatives
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
ATE296305T1 (en) 1997-11-25 2005-06-15 Antipodean Biotechnology Ltd ANTIOXIDANTS WITH SPECIFIC EFFECT ON MITOCHONDRIA
EP0941998B1 (en) 1998-03-03 2004-09-01 Pfizer Products Inc. 3,6-ketal macrolide antibiotics
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7169814B2 (en) * 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
RU2223103C1 (en) 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Pharmaceutical composition eliciting antibacterial effect
DK1592457T3 (en) 2003-01-27 2012-10-22 Endocyte Inc FOLATE-VINBLASTIN CONJUGATE AS MEDICINAL
WO2005062851A2 (en) 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
JP2005200419A (en) 2004-01-16 2005-07-28 National Health Research Inst Method for treating cancer
JP2007523912A (en) 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド Heparin for the treatment of ocular lesions
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ES2371931T3 (en) 2005-01-14 2012-01-11 Glaxo Group Limited MACROLID COMPOUNDS CONTAINING BIOTIN AND GROUP WITH PHOTO-AFFINITY FOR THE IDENTIFICATION OF THE MACROLID DIANA.
CN1706391A (en) 2005-05-09 2005-12-14 史同瑞 Terramycin suspension emulsion
JP5177429B2 (en) 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド Cancer treatment
CN1837229A (en) 2005-08-05 2006-09-27 济南思创生物技术有限公司 Clarithromycin derivatives and its preparation process and pharmaceutical application
DE102005039579B4 (en) 2005-08-19 2022-06-30 Magforce Ag Method for introducing therapeutic substances into cells
CN1837225A (en) 2005-08-23 2006-09-27 济南思创生物技术有限公司 Azithromycin derivatives and its preparation process and pharmaceutical application
WO2007139930A2 (en) 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
US20090311249A1 (en) 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
EP2526969A1 (en) 2006-09-07 2012-11-28 Stemline Therapeutics, Inc. Monitoring cancer stem cells
CN101631799A (en) 2006-10-30 2010-01-20 南方研究院 Target NBS1-ATM interact so that cancer cells to radiotherapy and chemotherapy sensitivity
SI2117520T1 (en) 2006-12-14 2019-01-31 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
DE102007025423A1 (en) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium derivatives for the targeted transport and release of substances into mitochondria and methods for their use
US20090099062A1 (en) 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
WO2009015214A2 (en) 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
EP2200653A2 (en) * 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
AU2008307544A1 (en) 2007-10-02 2009-04-09 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
WO2010121177A2 (en) 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
GB0912584D0 (en) 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
JP2013503171A (en) 2009-08-25 2013-01-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Use of metformin in the treatment and prevention of cancer
DK2338476T3 (en) * 2009-12-02 2012-09-17 Bettina Heil Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non-esterified fatty acid
SI2506840T1 (en) 2009-12-04 2021-08-31 OncoC4, Inc. Uses of hypoxia-inducible factor inhibitors
EP2544692A4 (en) 2010-03-10 2013-08-07 Univ Health Network Use of tigecycline for treatment of cancer
CN101810570B (en) * 2010-04-16 2012-06-20 成都师创生物医药科技有限公司 Lipid nano particle preparation containing composite formed fatty acid and anthracyclines antitumor antibiotics and preparation method thereof
US20110268722A1 (en) * 2010-04-22 2011-11-03 Siegelin Markus D Combination therapies with mitochondrial-targeted anti-tumor agents
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
WO2012107579A1 (en) 2011-02-10 2012-08-16 Ruprecht-Karls-Universität Heidelberg Hydrophobic modified peptides and their use for liver specific targeting
BR112013033239A2 (en) 2011-06-22 2016-09-06 Vyome Biosciences atifungic and antibacterial-based conjugate prodrugs
WO2013007708A1 (en) 2011-07-08 2013-01-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
CN102911226B (en) * 2011-08-03 2015-11-25 胡梨芳 Erythromycin octadecanoate compounds thing entity and uses thereof
WO2013019975A1 (en) 2011-08-03 2013-02-07 University Of Iowa Research Foundation Compositions and methods of treating cancer
US9180134B2 (en) 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
US9775855B2 (en) 2011-09-14 2017-10-03 Thomas J. Lewis Compositions comprising macrolide and tetracycline and their uses
WO2013130968A1 (en) 2012-03-01 2013-09-06 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics
WO2014036037A1 (en) 2012-08-28 2014-03-06 Annam Biosciences, Llc N-boc-dendrimers and their conjugates
US20150224169A1 (en) 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
CA3159085A1 (en) 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
MD4626C1 (en) 2013-04-24 2019-11-30 Smart Brain Sro Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
EP3016715A4 (en) 2013-07-01 2017-02-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN103536530A (en) 2013-10-30 2014-01-29 王玉万 Doxycycline hydrochloride long-acting injection and preparation method
US20150231069A1 (en) 2014-02-20 2015-08-20 Pankaj Modi Oral formulations of chemotherapeutic agents
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
EP3154596A4 (en) 2014-06-10 2018-01-24 Institute for Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
EP3206674B1 (en) 2014-10-17 2020-03-18 Targeted Therapies Research and Consulting Centre Multi-ingredient pharmaceutical composition for use in cancer therapy
CN104352566A (en) 2014-10-21 2015-02-18 河南牧翔动物药业有限公司 Oil-in-water compound chlortetracycline nanoemulsion
JP6439931B2 (en) 2015-02-26 2018-12-19 大日本印刷株式会社 Adsorption conveyance device and adsorption conveyance method
CN108136207A (en) 2015-10-06 2018-06-08 红山生物医药有限公司 For the conjoint therapy for the treatment of cancer
CN105884633B (en) 2016-05-07 2017-12-26 浙江大学 A kind of tetracycline stearic acid grafting and its preparation and application
CN109843931A (en) 2016-08-11 2019-06-04 昆士兰医学研究所理事会 Immunomodulatory compounds
CN106511317A (en) 2016-12-13 2017-03-22 浙江中同科技有限公司 Preparing method for taste masking clarithromycin granules
EP3570856A2 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
EP3570857A1 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018195446A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
RU2019142102A (en) 2017-05-19 2021-06-21 Лунелла Байотек, Инк. ANTIMITOSCINS: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS FOR ERADICATION OF MALIGNANT STEM CELLS
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy
JP7066847B2 (en) 2017-11-24 2022-05-13 ルネラ・バイオテック・インコーポレーテッド Triphenylphosphonium derivative compound that eradicates cancer stem cells
EP3728300A4 (en) 2017-12-20 2021-08-11 Lunella Biotech, Inc. Targeting mitochondrial fission through mdivi-1 derivatives

Also Published As

Publication number Publication date
RU2019142102A (en) 2021-06-21
AU2018270129A1 (en) 2020-01-16
WO2018213751A1 (en) 2018-11-22
BR112019024264A2 (en) 2020-06-02
CU20190092A7 (en) 2020-10-20
JP6938682B2 (en) 2021-09-22
ECSP19082194A (en) 2019-11-30
CL2019003283A1 (en) 2020-05-04
EP3624840A1 (en) 2020-03-25
RU2019142102A3 (en) 2021-06-21
EP3624840A4 (en) 2021-03-10
KR20200010343A (en) 2020-01-30
JP2020527127A (en) 2020-09-03
CN111315400A (en) 2020-06-19
CA3063717A1 (en) 2018-11-22
AU2018270129B2 (en) 2021-01-07
ZA202102509B (en) 2023-03-29
IL270598B (en) 2022-04-01
US11160821B2 (en) 2021-11-02
MX2019013735A (en) 2020-01-15
ZA201907654B (en) 2022-07-27
NZ760422A (en) 2023-11-24
US20200179424A1 (en) 2020-06-11
CO2019012888A2 (en) 2020-05-15
US20220072020A1 (en) 2022-03-10
DOP2019000294A (en) 2020-02-16
CA3063717C (en) 2021-08-24
CR20190524A (en) 2020-01-10
PE20200605A1 (en) 2020-03-10
US11865130B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
ZA202202712B (en) Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
BR112018012756A2 (en) heterocyclic compounds as immunomodulators
AU2018285213A1 (en) Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides
BR122020001787A8 (en) ANTIBODY-ACTIVE AGENT CONJUGATE, ITS PREPARATION METHODS, ITS COMPOSITION AND ITS USE
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
BR112014012985A2 (en) methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
TR201909461T4 (en) COMPOSITIONS OF THE PARASITICIAL ORAL VETERINARY CONTAINING SYSTEMIC ACTIVE SUBSTANCES, THEIR METHODS AND USES
BR112015018161A2 (en) LNA ANTISENSE OLIGOMER CONJUGATE, PHARMACEUTICAL COMPOSITION AND USE OF AN LNA ANTISENSE OLIGOMER CONJUGATE
WO2019090148A3 (en) Compositions and methods related to therapeutic cell systems for tumor growth inhibition
MX2022013612A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies.
MX2018011627A (en) Prodrugs of cytotoxic active agents having enzymatically cleavable groups.
AU2018280875A1 (en) Solid compositions for oral administration
BR112018013063A2 (en) bromodomain inhibitor and extra-terminal protein combination
BR112015015864A8 (en) pharmaceutical composition and use of a pharmaceutical composition
BR112017025698A2 (en) compositions and methods for inhibiting hif2alpha gene expression
MX2011012143A (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails.
MY197901A (en) Composition containing camellia sinensis extract
BR112018007068A2 (en) quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors
BR112017018198A2 (en) inhibition of olig2 activity
WO2016182139A3 (en) Composition, containing lithospermi radix extract as active ingredient, for preventing, alleviating, or treating peripheral neuropathy
PH12021551434A1 (en) Triple combination therapies for targeting mitochondria and killing cancer stem cells
WO2016186349A3 (en) Composition, containing quisaqualis indica extract, for preventing or treating prostatic hyperplasia
GEP201706717B (en) Fibrinolytic compositions comprising bromelain and nattokinase for prevention and treatment of phlebothrombtic states
Abd-Rabou et al. 5-fluorouracil synergized with raloxifene and cytosineβ-D-arabinofuranoside to combat colorectal cancers in vitro via controlling lipolysis
BR112018076014A2 (en) compositions comprising timolol and their use in the treatment of rosacea by topical administration